MRNA

MODERNA INC

Healthcare | Large Cap

-$0.97

EPS Forecast

$942.2

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Moderna’s Q3 2026 Playbook: Revenue Hits, Cash Builds, and a Fifth Product in the Spotlight

Overview: A quarter that leans into profitability without betraying the pipeline

Moderna, Inc. (MRNA) delivered a Q3 2026 that reads more like a portfolio update than a one-off earnings sprint. Revenue rose 29% year over year to about $1.3 billion, split roughly $780 million from the U.S. and $533 million from international markets. The company posted a GAAP net income of approximately $200 million, while the “net income” line on the press materials shows $162 million, underscoring the usual differences between GAAP and non-operating or one-off adjustments that a press release often teases but does not fully disclose in the narrative. Diluted earnings per share came in at $0.38 for the quarter, a meaningful step up from last year’s loss per share.

The takeaway here is less about a single line item and more about the operating rhythm Moderna is carving. The quarter benefited from higher COVID vaccine sales in international markets and a cadence of cost discipline that the company has been touting as part of its multi-year path to profitability and balance-sheet strength.

Key Financials and What They Suggest

  • Revenue and mix: Total revenue of $1.3B, with international sales contributing meaningfully to growth. The split—$780M U.S. vs. $533M international—highlights Moderna’s ongoing push into global markets and government partnerships that underpin recurring revenue streams.
  • Cost structure: Cost of sales was $318M, including $65M in third-party royalties. Cost of sales rose about 54% year over year, reflecting higher volume and manufacturing costs tied to international shipments and product mix.
  • R&D and SG&A: R&D expenses came in at $583M, down 27% versus the prior-year period as the company winds down certain late-stage infectious disease programs and pursues efficiency across the organization. SG&A was $282M, up 5% year over year, a reminder that growth investments stay on the books even as other costs retreat.
  • Income and EPS: Net income was $162M for Q3 2026; diluted EPS was $0.38. The year-over-year improvement in profitability is driven by top-line momentum and cost discipline, though the gap between GAAP and “net income” hints at the usual adjustments investors watch.
  • Cash position and capital actions: Cash, cash equivalents and investments stood at $8.0B as of September 30, 2026, up from $6.9B at the end of June. The company also highlighted $2.6B of net proceeds from convertible notes and capped calls, partially offset by a $950M Q1 litigation settlement payment and cash used in operations. Moderna now guides for an ending cash balance of $8.1–$8.3B for the year.

Outlook and Strategy: A modestly more ambitious revenue forecast, with a tighter cost frame

Moderna raised its 2026 revenue growth outlook to a 15%–25% range, up from a previous target of up to 10% growth. That shift signals more confidence in the company’s ability to translate pipeline progress and international expansion into sustained top-line gains. The narrative around mRNA vaccine updates and international partnerships remains central to this forecast, along with ongoing commercialization momentum for mFLUSIVA and other products.

The company also flagged continued progress in its commercial strategy, including the rollout of updated COVID vaccines, expansion of its respiratory vaccine portfolio, and international partnerships with the United Kingdom, Canada and Australia. A five-year distribution agreement with a local Mexican manufacturer for COVID-19 vaccines adds another layer to recurring revenue and geographic diversification.

Pipeline, Milestones, and Regulatory Highlights

Highlights include positive Phase 3 data for intismeran in melanoma and regulatory progress for mFLUSIVA, Moderna’s fifth approved product globally. These indicators matter for the company’s ability to sustain growth beyond vaccine sales and into a diversified biopharma profile. The combination of regulatory milestones and Phase 3 readouts helps anchor the EPS trajectory and revenue forecast in a more durable product lifecycle than “one vaccine win in one year.”

Balance Sheet and Cash Flow: A Flexible War Chest

The cash position suggests Moderna has built a buffer—$8.0 billion cash and equivalents as of late September, aided by convertible debt proceeds. The net proceeds of $2.6 billion from those financings are not trivial, but they come with a delicate balance: the company must manage potential dilution and interest/repayment dynamics while balancing its R&D needs and pipeline investments.

The cash trajectory, paired with the $950 million litigation settlement cash outlay earlier in the year, underpins a narrative of disciplined capital management. The company’s ability to fund ongoing clinical programs while delivering quarterly earnings per share in the vicinity of $0.38 without a major downshift in investments is a notable sign for investors tracking the sector’s cash-flow discipline.

Implications for Moderna and Peers

The Q3 results reinforce a thesis that Moderna’s strength in the near term sits at the intersection of vaccine cadence and a broader, mRNA-driven pipeline. The 15%–25% revenue growth outlook for 2026, supported by mFLUSIVA’s regulatory positioning and intismeran’s Phase 3 momentum, suggests the company is transitioning from a vaccine-dominated narrative to a more diversified biotech story. That matters for EPS consensus revisions and for investors seeking a long-run revenue forecast anchored by multiple platforms.

For sector peers, Moderna’s approach highlights a simple arithmetic: keep cash generation strong, push for regulatory milestones, and manage costs to improve margins as the pipeline matures. The company’s international expansion and government-partner revenue model could set a template for other vaccine and specialty biologics players facing similar pricing and contract dynamics.

In a market where earnings surprise is a frequent headline, Moderna’s sequential improvement in profitability and an elevated EPS figure amid a broadened product slate may tilt expectations for peers who rely on a handful of blockbuster products. The real test will be how seamlessly Moderna translates pipeline milestones into durable, quarterly profitability—without sacrificing the long tail of clinical programs that may define 2027 and beyond.

Conclusion: Momentum with a side of caution

Moderna’s Q3 2026 report offers a credible signal that the company is balancing a favorable revenue mix with disciplined cost management and meaningful regulatory and pipeline catalysts. The elevated 2026 revenue forecast, the cash runway, and the progress on mFLUSIVA and intismeran provide a coherent narrative for investors tracking MRNA and its biotech peers. The road ahead will test whether this quarter’s momentum can sustain a broader earnings trajectory and whether the company can convert pipeline progress into a durable EPS uplift that outpaces consensus over multiple quarters.

Ticker note: MRNA. Key terms to watch: EPS, earnings surprise, EPS consensus, revenue forecast, GAAP, net income, and the evolving revenue forecast as the year unfolds.

Disclaimer: This article synthesizes Moderna’s Q3 2026 results from publicly available disclosures and the company’s press release. Figures are presented for illustrative purposes and may reflect rounding or ongoing adjustments in subsequent filings.